生物活性：Balsalazide-d4 is deuterium labeled Balsalazide. Balsalazide could suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway.
IC50 & Target：IL-6
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Balsalazide-d4 相关抗体:
FOXP3 Antibody (YA858)
IL-1 beta Antibody
Phospho-STAT3 (Tyr705) Antibody (YA146)
STAT3 Antibody (YA056)
Phospho-STAT1 (Ser727) Antibody (YA148)
Phospho-STAT1 (Tyr701) Antibody
Phospho-STAT3 (Tyr705) Antibody
EpCAM Antibody (YA772)
FOXP3 Antibody
Phospho-STAT3 (Ser727) Antibody
STAT1 Antibody (YA059)
STAT1 Antibody (YA667)
STAT1 alpha Antibody
STAT2 Antibody (YA057)
STAT5a Antibody
STAT5b Antibody
STAT6 Antibody
Phospho-STAT5 (Tyr694) Antibody (YA145)
IL-1 beta Antibody (YA345)
CD127 Antibody
EpCAM Antibody (YA458)
FOXP3 Antibody (YA759)
IL-18 Antibody
IL-4 Antibody (YA343)
IL-6 Antibody
Phospho-STAT1 (Ser727) Antibody (YA149)
SOCS1 Antibody
STAT3 Antibody (YA666)
STAT4 Antibody
STAT5 Antibody
分子量：361.34
Formula：C17H11D4N3O6
CAS 号：2714315-25-8
非标记 CAS：80573-04-2
中文名称：巴柳氮-d4；巴沙拉嗪-d4
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (523 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[2]. Do EJ, et al. Suppression of colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway by balsalazide and VSL#3. J Gastroenterol Hepatol. 2016 Aug;31(8):1453-61.
 [Content Brief]
[3]. Kruis W, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut, 2001. 49(6): p. 783-789.
 [Content Brief]